Healthcare

EBOS Group is a major healthcare and animal-care distributor in Australia and New Zealand. Its essential role, broad scale, and strong cash generation stand out, while the main debate centers on whether those strengths can outweigh thin margins and higher leverage.

Denali Therapeutics is developing brain-penetrating medicines for neurodegenerative and rare diseases. Its appeal rests on a differentiated delivery platform, multiple partnered programs, and exposure to major unmet medical needs that could reshape its scale if clinical progress continues.

Definium Therapeutics is a development-stage biotech whose rising research investment and strong market momentum point to growing expectations around its pipeline. The analysis looks at whether that potential is enough to support a company still operating without meaningful revenue.

Curaleaf is one of the largest cannabis operators in the U.S., combining cultivation, branded products, wholesale, and dispensaries. Scale, improving free cash flow, and international exposure make it worth a closer look as margins and regulation evolve.

Clover Health is a Medicare Advantage insurer that has become much simpler and more focused. Revenue growth has accelerated, cash flow has improved, and losses have narrowed, making its progress worth a closer look for anyone studying long-term healthcare opportunities.

Celldex Therapeutics is building around barzolvolimab and other immune-focused programs aimed at diseases with meaningful unmet need. A clean balance sheet and a focused pipeline make the company notable, while upcoming clinical milestones remain central to its long-term outlook.

Clicks Group runs one of South Africa’s leading pharmacy and health-and-beauty retail networks, backed by pharmaceutical distribution. Steady sales growth, strong cash generation, and a resilient healthcare focus make its long-term profile worth a closer look.